GLP 1s for neurodegenerative diseases

GLP 1s for neurodegenerative diseases GLP-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes and obesity, are now being investigated for their potential neuroprotective effects in neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and others. Here’s an overview of the evidence and mechanisms: Potential Mechanisms of GLP-1 in Neurodegeneration Anti-inflammatory Effects … Read more